Emergent Biosolutions

emergent biosolutions - All News and Analysis

• Until Proven Otherwise, Sticking with Emergent BioSolutions

  Seeking Alpha - 2008-12-30

  Trader Mark submits: We said in our weekly missive we want to buy the best charts on buybacks and Emergent BioSolutions EBS is giving us a nice opportunity to add at the 20 day moving average (around $23.70). I am going to do so, but give a very large caveat...

  Tags: Biotech, Trader Mark, Emergent Biosolutions

• Emergent BioSolutions Looking Strong, Even on a Bad Day

  Seeking Alpha - 2008-12-01

  Trader Mark submits: Investors Business Daily has an article out on Emergent BioSolutions EBS that could read straight out of this blog - namely, it has a customer whose pockets are endless and a long sight line on revenue a rarity in this market. Remember, we have two names who...

  Tags: Biotech, Trader Mark, Emergent Biosolutions

• Emergent BioSolutions Inc. Q3 2008 Earnings Call Transcript

  Seeking Alpha - 2008-11-20

  Question-and-Answer SessionOperator Operator instructions. And our first question comes from the line of Eric Schmidt with Cowen & Company. Please proceed. Eric Schmidt – Cowen & Company Good afternoon, gentlemen. Congratulations on a nice quarter. Don, last quarter, you had us believe that the revenues would come in...

  Tags: Revenue, Eric Schmidt, Cowen & Co., Call Transcript, Earnings, Operational Accounting, Finance, Seeking Alpha, Emergent Biosolutions

• Emergent BioSolutions Files Shelf Registration

  Seeking Alpha - 2008-11-13

  Trader Mark submits: One of the few stocks with a chart worth buying is down 12% today on a shelf registration of "up to" $100M. This is too bad since it's an overhang for now, especially for a company of only $600M in market cap - that is potentially some...

  Tags: Registration Statement, Emergent Biosolutions, Common Stock, Seeking Alpha, Shelf Registration, Trader Mark, Biotech

• Emergent BioSolutions' Blowout Quarter

  Seeking Alpha - 2008-11-06

  Trader Mark submits: I almost bought Emergent BioSolutions EBS today on the pullback to support (20 day moving average) to fill my 2 stock "government as customers" portfolio - but with earnings tonight I wanted to hold off. And what an earnings they are - EBS should be on Jimmy...

  Tags: Revenue, Net Income, Analyst, Emergent Biosolutions, Seeking Alpha, Trader Mark, Sales Strategy, Operational Accounting, Product Development, Sales, Finance, Research & Development, Business Operations, Biotech

• Emergent BioSolutions: Stellar Acting Stock

  Seeking Alpha - 2008-10-22

  Trader Mark submits: I asked readers last week if they had any stocks on their screens that fulfilled some criteria in this quite brutal marketI am curious on your watch lists and holdings if you technical types out there can find stocks over both their 50 and 200 day moving...

  Tags: Trader, Stock, Emergent Biosolutions, Seeking Alpha, Trader Mark, Investment, Finance, Biotech

• U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax® and Anthrax Immune Globulin under Prep Act

  - 2008-10-09

  HHS Secretary Determines That Potential Threat of Exposure to Anthrax Constitutes a Public Health Emergency ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that two medical countermeasures included in its anthrax franchise -- BioThrax[R] Anthrax Vaccine Adsorbed and Anthrax Immune Globulin AIG -- have been included as...

  Tags: declaration, Emergent Biosolutions, HEALTHCARE, U.S. Department of Health and Human Services, U.S. Government

• U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million

  - 2008-10-01

  New Contract Extends USG's Commitment to Purchase BioThrax Through 3Q 2011 and is a Follow-on to the Existing 2007, $448 Million Contract ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and...

  Tags: Emergent Biosolutions, FDA, Government, HEALTHCARE, procurement, U.S. Department of Health and Human Services, U.S. Government, vaccine

• Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine

  - 2008-09-26

  --AV7909 Contract is in Addition to Recently Announced $24 Million Development Contract for Anthrax Monoclonal and Pending Proposal to Supply HHS with Up to 25 Million Doses of a Recombinant Anthrax Vaccine ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with BARDA/NIAID,...

  Tags: Emergent Biosolutions, HEALTHCARE, U.S. Department of Health and Human Services, vaccine

• Emergent BioSolutions: Surprising Value Play

  Seeking Alpha - 2008-09-12

  Saj Karsan submits: Emergent BioSolutions Inc. (NYSE: EBS) does not have the makings of an ideal value stock. Assessing this small pharmaceutical company, value investors would tend to worry about the risks of being too reliant on only a few drugs. We discussed here how the diversity of large pharma...

  Tags: Emergent Biosolutions, Biotech

• Emergent BioSolutions Inc. Q2 2008 Earnings Call Transcript

  Seeking Alpha - 2008-08-07

  Question-and-Answer Session Operator Thank you. Operator instructions Your first question comes from the line of Eric Schmidt representing Cowen & Company. Please proceed. Eric Schmidt – Cowen & Company Hi, good morning. Thanks for taking my call. Don, in terms of the operating cash used in the quarter, are...

  Tags: Emergent Biosolutions

• Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine

  - 2008-07-31

  The company's submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has submitted a proposal in response to a request for proposal...

  Tags: Emergent Biosolutions, HEALTHCARE, procurement, RFP, U.S. Department of Health and Human Services, vaccine

• Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate

  - 2008-06-05

  * Study designed to confirm safety and immunogenicity of vaccine manufactured at the large-scale commercial facility planned for launch

  Tags: Emergent Biosolutions

• Emergent BioSolutions and the European Corporate Security Association Sponsor a Conference on Bioterrorism

  - 2008-06-05

  Attendees Include Key Officials from the European Union, International and Diplomatic Institutions

  Tags: bioterrorism, Emergent Biosolutions

• Emergent BioSolutions to Webcast Presentation at the Jefferies and Company 2nd Annual Healthcare Conference on June 25, 2008

  - 2008-06-04

  ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Jefferies and Company 2nd Annual Healthcare Conference scheduled for Wednesday June 25, 2008 at 3:45 pm Eastern. A member of the company's senior management team will provide a corporate overview, including...

  Tags: Emergent Biosolutions, Webcast

• Rockville-based Emergent BioSolutions buys Protein Sciences

  - 2008-05-28

  Emergent BioSolutions is purchasing Protein Sciences Corp., which makes the next-generation flu vaccine the government has put on the fast-track approval process, The Washington Post reported. Rockville- based Emergent could pay more than $75 million for Protein Sciences, based in Meriden, Conn., the newspaper said in its Tuesday editions. According...

  Tags: Emergent Biosolutions

• Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok®, and Related Novel Platform Technology

  - 2008-05-27

  * FluBlok BLA granted fast track status and priority review by FDA; would be the first licensed recombinant hemagglutinin cell culture influenza vaccine

  Tags: Emergent Biosolutions, vaccine

• Emergent BioSolutions Reports Financial Results for First Quarter 2008

  - 2008-05-07

  -- Continued delivery of BioThrax[R] doses under current HHS contract drives 62 percent increase in first quarter revenue -- Continued investment in pipeline through internally generated cash flows -- 2008 financial outlook reaffirmed ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for...

  Tags: Emergent Biosolutions, FINANCE, financial, HEALTHCARE, R&D, revenue, SALES, U.S. Department of Health and Human Services, vaccine

• Emergent BioSolutions Inc. Q1 2008 Earnings Call Transcript

  Seeking Alpha - 2008-05-07

  Question-and-Answer Session Operator Operator instructions And your first question comes from the line of Richard Smith with JP Morgan. Please proceed. Richard Smith – JP Morgan Yes, good morning everyone. Fuad El-Hibri Good morning. Don Elsey Good morning Rich. Richard Smith – JP Morgan Good morning. Just a quick...

  Tags: Emergent Biosolutions

• Emergent's Vaccine Play: Biotech Can Flip-Flop, Too

  BNET - 2008-05-06

  For sudden twists of fate, abrupt collapses and the occasional stunning revival, it's hard to beat the biotech industry. Yesterday, for instance, the all-but-dead biotech VaxGen agreed to sell off its ailing anthrax vaccine to its East Coast rival Emergent BioSolutions --a company that spent much of this decade trying...

  Tags: Biotechnology, Vaccine, Emergent Biosolutions, VaxGen, Healthcare, David P. Hamilton

• Incorporated: 1998
• CEO: Mr. Fuad El-Hibri